RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Redhill Biopharma Reports Further Analysis Of Phase 2/3 Data Including A 62% Reduction In Mortality With Oral Opaganib In Moderately Severe Covid 19 Patients

Facebook Comments

Leave a Reply

CommentLuv badge